Atle Fund Management AB
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 4, 2025), Atle Fund Management AB reported 36 stock positions worth $210.8 million. Its top holding was Eli Lilly (LLY) at 13.6% of the portfolio, followed by Unitedhealth (UNH, 8.5%) and Abbvie (ABBV, 7.6%). Compared with Q3 2024, it opened 3 new positions, sold out of 3, added to 22 and reduced 7. The biggest buy was Abbvie (ABBV, shares +104%) and the biggest sale an exit from Regeneron Pharmaceuticals (REGN).
- Most Recent 13F
- Q2 2026
- Location
- STOCKHOLM, V7
- CIK
- 0001381843
- Portfolio Value
- $210.8M (Q4 2024)
- SEC Filing
- 0001381843-25-000002 ↗ filed Feb 4, 2025
Holdings Value
Holdings 36 stocks · $210.8M
| LLY Eli Lilly & Co. | 13.60% | 37,068 | $28.7M | Add +21.3% |
| UNH Unitedhealth Group Inc. | 8.48% | 35,202 | $17.9M | Reduce -0.8% |
| ABBV Abbvie Inc. | 7.58% | 90,723 | $16.0M | Add +103.9% |
| BSX Boston Scientific Corp. | 6.56% | 154,222 | $13.8M | Add +45.3% |
| TMO Thermo Fisher Scientific Inc. | 6.13% | 24,896 | $12.9M | Add +13.1% |
| MRK Merck & Co. Inc. | 4.93% | 105,727 | $10.4M | Reduce -31.7% |
| SYK Stryker Corp. | 4.41% | 25,660 | $9.3M | Add +9.4% |
| NBIX Neurocrine Biosciences Inc. | 4.41% | 67,763 | $9.3M | Add +11.8% |
| ALKS Alkermes PLC | 3.64% | 266,499 | $7.7M | Add +12.6% |
| VRTX Vertex Pharmaceuticals Inc. | 3.60% | 22,257 | $7.6M | Add +31.0% |
| COR Cencora Inc. | 3.47% | 32,553 | $7.3M | Reduce -10.9% |
| AMGN Amgen Inc. | 3.37% | 27,414 | $7.1M | Reduce -5.3% |
| ITCI Intra-Cellular Therapies Inc. | 2.82% | 71,138 | $5.9M | Reduce -15.9% |
| EW Edwards Lifesciences Corp. | 2.40% | 68,296 | $5.1M | Add +87.1% |
| MIRM Mirum Pharmaceuticals Inc. | 2.28% | 116,692 | $4.8M | Reduce -15.6% |
| DXCM Dexcom Inc. | 2.22% | 60,057 | $4.7M | Add +11.7% |
| HRMY Harmony Biosciences Holdings | 1.95% | 120,501 | $4.1M | Reduce -20.7% |
| CAH Cardinal Health Inc. | 1.72% | 30,680 | $3.6M | Add +11.6% |
| NAMS Newamsterdam Pharma Co. NV | 1.69% | 138,983 | $3.6M | No change |
| ACLX Arcellx Inc. | 1.56% | 42,071 | $3.3M | Add +4.6% |
| UFPT Ufp Technologies Inc. | 1.50% | 23,159 | $3.2M | Add +28.3% |
| FOLD Amicus Therapeutics Inc. | 1.46% | 326,840 | $3.1M | Add +18.6% |
| BBIO Bridgebio Pharma Inc. | 1.33% | 103,032 | $2.8M | Add +92.8% |
| RVMD Revolution Medicines Inc. | 1.27% | 62,161 | $2.7M | New |
| MRUS Merus NV | 1.24% | 62,521 | $2.6M | Add +23.4% |
| JANX Janux Therapeutics Inc. | 0.99% | 39,573 | $2.1M | New |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 0.95% | 10,900 | $2.0M | New |
| KRYS Krystal Biotech Inc. | 0.70% | 9,202 | $1.5M | No change |
| MREO Mereo Biopharma Group PL-ADR | 0.65% | 390,000 | $1.4M | Add +95.0% |
| SMMT Summit Therapeutics Inc. | 0.62% | 101,177 | $1.3M | Add +17.6% |
| CRBP Corbus Pharmaceuticals Holdi | 0.56% | 98,304 | $1.2M | Add +41.3% |
| AUTL Autolus Therapeutics PLC | 0.50% | 479,644 | $1.1M | Add +8.4% |
| SLNO Soleno Therapeutics Inc. | 0.47% | 30,940 | $985K | Add +17.2% |
| MERSANA THERAPEUTICS INC | 0.36% | 538,621 | $765K | No change |
| PHVS Pharvaris NV | 0.31% | 34,328 | $653K | No change |
| CABA Cabaletta Bio Inc. | 0.26% | 247,454 | $554K | Add +46.8% |
Portfolio Sells Q3 2024 → Q4 2024
| REGN Regeneron Pharmaceuticals | Sold out | 0.00% | −3.47 |
| MRK Merck & Co. Inc. | Reduce -31.7% | 4.93% | −3.32 |
| IONS Ionis Pharmaceuticals Inc. | Sold out | 0.00% | −1.56 |
| UNH Unitedhealth Group Inc. | Reduce -0.8% | 8.48% | −1.28 |
| AMGN Amgen Inc. | Reduce -5.3% | 3.37% | −1.02 |
| HRMY Harmony Biosciences Holdings | Reduce -20.7% | 1.95% | −0.91 |
| IMCR Immunocore Holdings PLC-ADR | Sold out | 0.00% | −0.79 |
| COR Cencora Inc. | Reduce -10.9% | 3.47% | −0.40 |
| MIRM Mirum Pharmaceuticals Inc. | Reduce -15.6% | 2.28% | −0.26 |
| ITCI Intra-Cellular Therapies Inc. | Reduce -15.9% | 2.82% | −0.09 |
Portfolio Buys Q3 2024 → Q4 2024
| ABBV Abbvie Inc. | Add +103.9% | 7.58% | +3.45 |
| BSX Boston Scientific Corp. | Add +45.3% | 6.56% | +2.38 |
| RVMD Revolution Medicines Inc. | New | 1.27% | +1.27 |
| EW Edwards Lifesciences Corp. | Add +87.1% | 2.40% | +1.27 |
| NBIX Neurocrine Biosciences Inc. | Add +11.8% | 4.41% | +1.12 |
| JANX Janux Therapeutics Inc. | New | 0.99% | +0.99 |
| ONC Beone Medicines Ltd.-ADR | New | 0.95% | +0.95 |
| LLY Eli Lilly & Co. | Add +21.3% | 13.60% | +0.88 |
| BBIO Bridgebio Pharma Inc. | Add +92.8% | 1.33% | +0.70 |
| DXCM Dexcom Inc. | Add +11.7% | 2.22% | +0.53 |
| ALKS Alkermes PLC | Add +12.6% | 3.64% | +0.52 |
| SYK Stryker Corp. | Add +9.4% | 4.41% | +0.43 |
| CAH Cardinal Health Inc. | Add +11.6% | 1.72% | +0.29 |
| MREO Mereo Biopharma Group PL-ADR | Add +95.0% | 0.65% | +0.26 |
| FOLD Amicus Therapeutics Inc. | Add +18.6% | 1.46% | +0.08 |
| MRUS Merus NV | Add +23.4% | 1.24% | +0.05 |
| ACLX Arcellx Inc. | Add +4.6% | 1.56% | −0.02 |
| CABA Cabaletta Bio Inc. | Add +46.8% | 0.26% | −0.11 |
| CRBP Corbus Pharmaceuticals Holdi | Add +41.3% | 0.56% | −0.11 |
| VRTX Vertex Pharmaceuticals Inc. | Add +31.0% | 3.60% | −0.11 |
| SLNO Soleno Therapeutics Inc. | Add +17.2% | 0.47% | −0.16 |
| AUTL Autolus Therapeutics PLC | Add +8.4% | 0.50% | −0.25 |
| SMMT Summit Therapeutics Inc. | Add +17.6% | 0.62% | −0.26 |
| TMO Thermo Fisher Scientific Inc. | Add +13.1% | 6.13% | −0.27 |
| UFPT Ufp Technologies Inc. | Add +28.3% | 1.50% | −1.19 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $371.7M | LLY, MRK, JNJ, ABBV, CVS |
| Q1 2026 | 39 | $309.7M | LLY, MRK, TMO, ONC, JNJ |
| Q4 2025 | 39 | $313.4M | LLY, ABBV, MRK, TMO, NBIX |
| Q3 2025 | 38 | $27.0M | LLY, ABBV, NBIX, MRK, TMO |
| Q2 2025 | 37 | $233.7M | LLY, ABBV, BSX, NBIX, MRK |
| Q1 2025 | 37 | $226.5M | LLY, ABBV, UNH, BSX, MRK |
| Q4 2024 | 36 | $210.8M | LLY, UNH, ABBV, BSX, TMO |
| Q3 2024 | 36 | $212.8M | LLY, UNH, MRK, TMO, AMGN |
| Q2 2024 | 38 | $164.0M | LLY, UNH, MRK, TMO, AMGN |
| Q1 2024 | 44 | $164.4M | MRK, LLY, UNH, TMO, NBIX |